Komipharm International

KOSDAQ-041960
KOSDAQ
Biological Products, Except Diagnostic Substances
Global Rank
#18520
Country Rank
#541
Market Cap
264.94 M
Price
3.73
Change (%)
2.08%
Volume
114,656

KOSDAQ-041960's Next Dividend

Next Estimated Amount
₩3.69
Next Estimated Pay Date
04/10/2005
Last Amount
₩3.69
Last Pay Date
04/16/2004
Dividend Shot Clock Ex-Date: 12/29/2003
0
Days
0
Hours
0
Minutes
0
Seconds
Ex-dividend date passed

Komipharm International Dividend Chart

*Amounts are shown in the stock exchange currency (KRW) for convenience

Komipharm International(KOSDAQ-041960) Dividend History

Komipharm International (KOSDAQ-041960) currently pays an annual dividend of $0.00 per share, offering a dividend yield of 0.77%. The next dividend payout date has not been announced.
Ex-Dividend Date Amount Adj. Amount Dividend Yield Pay Date Change (%)
2003 ₩150 ₩3.69 200%
12/29/2003 ₩150 ₩3.69 0.77% 04/16/2004 200%
2002 ₩50 ₩1.23 -50%
12/27/2002 ₩50 ₩1.23 0.20% 04/23/2003 -50%
2001 ₩100 ₩2.46
12/27/2001 ₩100 ₩2.46 0.27% 04/19/2002
*Amounts are shown in the stock exchange currency (KRW) for convenience
*Historical information is adjusted for stock splits

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.